The standard on sleep problems and hypnotics of the Dutch College of General Practitioners (First revision);NHG-standaard slaapproblemen en slaapmiddelen: Eerste herziening

Huisarts en Wetenschap

Volumn 48, Issue 8, 2005, Pages 402-415

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BROMAZEPAM; BROTIZOLAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; LOPRAZOLAM; LORMETAZEPAM; MEDAZEPAM; MIDAZOLAM; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; PRAZEPAM; TEMAZEPAM; ZOLPIDEM; ZOPICLONE;

GENERAL PRACTITIONER; HUMAN; INSOMNIA; NARCOLEPSY; NETHERLANDS; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP INDUCTION; STANDARD;

EID: 24144497695     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Anonymus. Diagnostic classification of sleep and arousal disorders. Association of Sleep Disorders Centers and the Association for the Psychophysiological Study of Sleep. Sleep 1979;2:1-154.
2. Anonymus. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984;251:2410-4.
3. Anonymus. Visuele hallucinaties in samenhang met gebruik zolpidem. GeBu Prikbord 1996;30:121.
4. Anonymus. Gebruik van benzodiazepinen 1993-1998. Geneesmiddel Informatie Project van het College voor Zorgverzekeringen. Amstelveen: College voor Zorgverzekeringen, 2000.
5. Anonymus. British National Formulary. 44th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003a.
6. Anonymus. Gegevens Stichting Farmaceutische Kengetallen, 2003b. http://www.sfk.nl
7. Anonymus. Geneesmiddelen, zwangerschap en borstvoeding. 3e druk. Bilthoven: Stichting Health Base/Teratologie Informatie Centrum RIVM, 2003c.
8. Anonymus. Managing patients with restless legs. Drug Ther Bull 2003d;41:81-3.
9. Aserinsky E, Kleitman M. Regularly occuring periods of eye motility, and concomitant phenomena during sleep. Science 1953;18:273-4.
10. Baillargeon L, Demers M, Ladouceur R. Stimulus-control: nonpharmacologic treatment for insomnia. Can Fam Physician 1998;44:73-9.
11. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Gregoire JP Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003;169:1015-20.
12. Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002;8:5-21.
13. Beersma DGM. Chronobiologie van de slaap. In: Van Bemmel AL, Beersma DGM, De Groen JHM, Hofman WF, redactie. Handboek Slaap en Slaapstoornissen. Maarssen: Elsevier gezondheidszorg, 2001.
14. Boot P, Eekhof JAH, Knuistingh Neven A. Restless legs-syndroom. Huisarts Wet 2003;46:573-6.
15. Breimer DD. Slaapmiddelen en slapeloosheid: verslag van een 'Consensus Development Conference'. Ned Tijdschr Geneeskd 1985;129:735-7.
16. Bridgman SA, Dunn KM. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 2000;2:CD001004.
17. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45-58.
18. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
19. CBG (College ter Beoordeling van Geneesmiddelen). Geneesmiddeleninformatiebank (2005). http://www.cbg-meb.nl: geraadpleegd 9 mei 2005.
20. Commissie Farmaceutische Hulp. Farmacotherapeutisch kompas 2004. Amstelveen: College voor Zorgverzekeringen, 2004.
21. Cormack MA, Sweeney KG, Hughes-Jones H, Foot GA. Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. Br J Gen Pract 1994;44:5-8.
22. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003;17:825-37.
23. Dana C, Peny B, Schoemaker H, Benavides J. Autoradiographic distritubion of ω (benzodiazepine) modulatory sites subunits in primate brain. Can J Physiol Pharmacol 1994;72 (Suppl 1):337.
24. De Groen JHM, Cluydts R. Dyssomnieën. In: Van Bemmel AL, Beersma DGM, De Groen JHM, Hofman WF, redactie. Handboek Slaap en Slaapstoornissen. Maarssen: Elsevier gezondheidszorg, 2001a.
25. De Groen JHM, Van Keimpema ARJ, Van der Meulen FW. Diagnostiek en behandeling van het obstructieve slaapapneu syndroom (OSAS) (bij volwassenen). Uitgave van de Nederlandse Vereniging voor Slaap-Waak Onderzoek (NSWO), onder auspiciën van het Kwaliteitsinstituut voor de gezondheidszorg CBO. Alphen a/d Rijn: Van Zuiden, 2001b.
26. Declerq T, Rogiers R, Habraken H, Michels J, Mariman A. Aanbeveling slapeloosheid op de eerste lijn. Berchem: Wetenschappelijke Vereniging van Vlaamse Huisartsen, 2005.
27. Diagnostic Classification Steering Committee of the American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual. Lawrence/Rochester, Minn.: American Sleep Disorders Association, 1990.
28. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000;33:47-53.
29. Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004;8:iii-x, 1-125.
30. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001;285:1856-64.
31. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003;26:177-82.
32. Eijkelenboom PR, Springer MP, Dekker FN. Het Leidse slaapprotocol: de bruikbaarheid in de huisartspraktijk van een protocol voor de diagnostiek en behandeling van slaapklachten. Huisarts Wet 1992;35:465-9.
33. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 1998;36:195-203.
34. Engle-Friedman M, Bootzin RR, Hazlewood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol 1992;48:77-90.
35. Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther 2001;39:45-60.
36. Evans JG. Drugs and falls in later life. Lancet 2003;361:448.
37. Gorgels WJ, Oude Voshaar RC, Mol AJ, Breteler MH, Van de Lisdonk EH, Zitman FG. Het langdurig gebruik van benzodiazepinen. Ned Tijdschr Geneeskd 2001;145:1342-6.
38. Guilleminault C, Clerk A, Black J, Labanowski M, Pelayo R, Claman D. Nondrug treatment trials in psychophysiologic insomnia. Arch Intern Med 1995;155:838-44.
39. Guilleminault C, Anagnos A. Narcolepsy. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
40. Hajak G, Bandelow B, Zulley J, Pittrow D. «As needed» pharmacotherapy combined with stimulus control treatment in chronic insomnia-assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 2002a;14:1-7.
41. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, Sonka K, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002b;17:9-17.
42. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98:1371-8.
43. Harvey AG, Tang NK. Cognitive behaviour therapy for primary insomnia: can we rest yet? Sleep Med Rev 2003;7:237-62.
44. Hauri PJ. Primary insomnia. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
45. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002;2:CD001520.
46. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev 2002;4:CD003346.
47. Hoekema A, Wijkstra PJ, Buiter CT, Van der Hoeven JH, Meinesz AF, De Bont LG. Behandeling van het obstructieve slaapapneusyndroom bij volwassenen. Ned Tijdschr Geneeskd 2003;147:2407-12.
48. Hoekema A, Stegenga B, De Bont LG. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med 2004;15:137-55.
49. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ 2000a;162:216-20.
50. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000b;162:225-33.
51. Horne JA. Two types of sleep and sleepiness. In: Koella WP, Obal F, Schulz H, editors. Sleep '86. Stuttgart: Gustav Fischer, 1988.
52. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004;164:1888-96.
53. Janson C, Lindberg E, Gislason T, Elmasry A, Boman G. Insomnia in men-a 10-year prospective population based study. Sleep 2001;24:425-30.
54. Jones IR, Sullivan G. Physical dependence on zopiclone: case reports. BMJ 1998;316:117.
55. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
56. Kerkhof GA. Brain potentials at different times of day for morning-type and evening-type subjects [Proefschrift]. Leiderdorp, 1981.
57. Kerkhof GA. Circadiane ontregeling en slaapstoornissen. In: Kerkhof GA, redactie. Slaap-waakstoornissen: ontregelingen van de biologische klok. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, Rijksuniversiteit Leiden, 1998.
58. King MB, Gabe J, Williams P, Rodrigo EK. Long term use of benzodiazepines: the views of patients. Br J Gen Pract 1990;40:194-6.
59. Knuistingh Neven A. Slapen: een soms adembenemende bezigheid. Het slaapapneusyndroom in de huisartspraktijk. Huisarts Wet 1997;40:533-5.
60. Knuistingh Neven A, Eekhof JAH. Jet lag. Huisarts Wet 2004;47:430-2.
61. Kooiker SE. De consumenten van geneesmiddelen. In: Van den Berg Jeths A, Peters-Volleberg GWM, redactie. Geneesmiddelen en medische hulpmiddelen: trends en dilemma's. Houten: Bohn Stafleu Van Loghum, 2002:84-98.
62. Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine. 3th ed. Philadelphia: Saunders, 2000a.
63. Kryger MH. Management of obstructive sleep apnea-hypophea syndrome. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000b.
64. Kupfer DJ, Reynolds CF 3rd. Management of insomnia. N Engl J Med 1997;336:341-6.
65. Lamberg L. Sleep specialists weigh hypnotics, behavioral therapies for insomnia. JAMA 1997;278:1647-9.
66. Landi F, Cesari M, Russo A, Onder G, Sgadari A, Bernabei R. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther 2002;72:729-34.
67. Landolt HP, Werth E, Borbely AA, Dijk DJ. Caffeine intake (200 mg) in the morning affects human sleep and EEG power spectra at night. Brain Res 1995a;675:67-74.
68. Landolt HP, Dijk DJ, Gaus SE, Borbely AA. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology 1995b;12:229-38.
69. Landolt HP, Roth C, Dijk DJ, Borbely AA. Late-afternoon ethanol intake affects nocturnal sleep and the sleep EEG in middle-aged men. J Clin Psychopharmacol 1996;16:428-36.
70. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9.
71. Lim J, Lasserson TJ, Fleetham J, Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2004;4: CD004435.
72. McGregor C, Machin A, White JM. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev 2003;22:175-80.
73. Mendelson WB. Hypnotics: basic mechanisms and pharmacology. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
74. Merica H, Gaillard JM. Statistical description and evaluation of the interrelationships of standard sleep variables for normal subjects. Sleep 1985;8:261-73.
75. Mignot E. Pathophysiology of narcolepsy. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
76. Montgomery P, Dennis J. Physical exercise for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2002;4:CD003404.
77. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003;1:CD003161.
78. Montplaisir J, Nicolas A, Godbout R, Walters A. Restless legs syndrome and periodic leg movement disorder. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
79. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a metaanalysis of treatment efficacy. Am J Psychiatry 1994;151:1172-80.
80. Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999;22:1134-56.
81. Morin CM, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther 2002;40:741-52.
82. Morin CM. Measuring outcomes in randomized clinical trials of insomnia treatments. Sleep Med Rev 2003;7:263-79.
83. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995;63:79-89.
84. Nagtegaal JE, Kerkhof GA, Smits MG, Swart AC, Van Der Meer YG. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res 1998;7:135-43.
85. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia. A meta-analysis of treatment efficacy. JAMA 1997;278:2170-7.
86. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
87. Okkes IM, Oskam SK, Lamberts H. Van klacht naar diagnose: episodegegevens uit de huisartspraktijk. Bussum: Coutinho, 1998.
88. Oude Voshaar RC. Consecutive treatment strategies to discontinue long-term benzodiazepine use: a systematic evaluation in general practice [Proefschrift]. Nijmegen: Katholieke Universiteit Nijmegen, 2003a.
89. Oude Voshaar RC, Gorgels WJ, Mol AJ, Van Balkom AJ, Van de Lisdonk EH, Breteler MH, et al. Tapering off long-term benzodiazepine use with or without group cognitive-beharioural therapy: three-condition, randomised controlled trial. Br J Psychiatry 2003b;182:498-504.
90. Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg 2003;58:27-36.
91. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997;276:1265-8.
92. Post D. Het gebruik van benzodiazepines in de huisartspraktijk: een onderzoek in eigen huis. Med Cont 1982;37:896-9.
93. Poyares DR, Guilleminault C, Ohayon MM, Tufik S. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry 2002;26:539-45.
94. Prodigy. Guidance - insomnia (2003). http://www. prodigy.nhs.uk/guidance. asp?gt=insomnia.
95. Roehrs T, Roth T. Hypnotics: efficacy and adverse effects. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
96. Roth T, Hajak G, Ustun TB. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001;55:42-52.
97. Rover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38.
98. Salinsky JV, Dore CJ. Characteristics of long term benzodiazepine users in general practice. J R Coll Gen Pract 1987;37:202-4.
99. Schaefer C. Drugs during pregnancy and lactation: handbook of prescription drugs and comparative risk assessment. Amsterdam: Elsevier, 2001.
100. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 1988;78:706-11.
101. Schoiker SL, Bertelson AD, Lacks P. Is sleep hygiene a sufficient treatment for sleep maintenance insomnia? Behav Res Ther 1988;19:183-90.
102. Schrader H, Bovim G, Sand T. The prevalence of delayed and advanced sleep phase syndromes. J Sleep Res 1993;2:51-5.
103. Sikdar S, Ruben SM. Zopiclone abuse among polydrug users. Addiction 1996;91:285-6.
104. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999;14:287-303.
105. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003;7:215-25.
106. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. 2000;1:91-9.
107. Swinkels H. Huisarts en patient in cijfers: enkele gegevens uit de gezondheidsenquête van het CBS. Huisarts Wet 1990;33:504-10.
108. Theunissen D, Knuistingh Neven A, Uges D. Medicamenteuze therapie. In: Van Bemmel AL, Beersma DGM, De Groen JHM, Hofman WF, redactie. Handboek Slaap en Slaapstoornissen. Maarssen: Elsevier gezondheidszorg, 2001.
109. Thorpy MJ. Classification of sleep disorders. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
110. Trenkwalder C, Hundemer HP, Lledo A, Swieca J, Polo O, Wetter TC, et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004;62:1391-7.
111. Tsai MJ, Huang YB, Wu PC. A novel clinical pattern of visual hallucination after zolpidem use. J Toxicol Clin Toxicol 2003;41:869-72.
112. Tsutsui S. A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia. J Int Med Res 2001;29:163-77.
113. Tyrer P. Risks of dependence on benzodiazepine drugs: the importance of patient selection. BMJ 1989;298:102, 104-5.
114. Van Cauter E. Endocrine physiology. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: Saunders, 2000.
115. Van den Bossche RAS, Peeters EAJ, De Weerd AW. 's Morgens moeilijk wakker worden bij tieners: gedragsprobleem, misperceptie of slaapstoornis? Ned Tijdschr Geneeskd 2004;148:301-4.
116. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Utrecht/ Bilthoven: NIVEL/Rijksinstituut voor Volksgezondheid en Milieu, 2004.
117. Van der Ree CM. Volume en kosten van farmaceutische hulp bij verschillende vormen van recepten: kwaliteitsverbetering en kostenbesparing mogelijk? Med Cont 1991;44:1309-12.
118. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van ZM, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
119. Van Dijk JG, Bollen EL, Slootweg J, Van der Meer CM, Durian FW, Zwinderman AH. Geen verschil in werkzaamheid tussen hydrokinine en placebo bij 'restless legs'-syndroom. Ned Tijdschr Geneeskd 1991;135:759-63.
120. Van Hulten R. Blue boy - why not? Studies of benzodiazepine use in a Dutch community [Proefschrift]. Utrecht: Rijksuniversiteit Utrecht, 1998.
121. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-328.
122. Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, et al. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2001;251:117-23.
123. Voderholzer U, Al Shajlawi A, Weske G, Feige B, Riemann D. Are there gender differences in objective and subjective sleep measures? A study of insomniacs and healthy controls. Depress Anxiety 2003;17:162-72.
124. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23:1087-96.
125. Waterman D, Hofman WF. Niet-medicamenteuze therapie. In: Van Bemmel AL, Beersma DGM, De Groen JHM, Hofman WF, redactie. Handboek Slaap en Slaapstoornissen. Maarssen: Elsevier gezondheidszorg, 2001.
126. Wetter DW, Fiore MC, Baker TB, Young TB. Tobacco withdrawal and nicotine replacement influence objective measures of sleep. J Consult Clin Psychol 1995;63:658-67.
127. White J, Cates C, Wright J. Continuous positive airways pressure for obstructive sleep apnoea. Cochrane Database Syst Rev 2002;2: CD001106.
128. Zandstra SM, Van Rijswijk E, Rijnders CA, Van de Lisdonk EH, Bor JH, Van Weel C, et al. Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam Pract 2004;21:266-9.
129. Zeman A, Britton T, Douglas N, Hansen A, Hicks J, Howard R, et al. Narcolepsy and excessive daytime sleepiness. BMJ 2004;329:724-8.
130. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia-a randomized, double-blind, comparative clinical study. Eur J Med Res 2002;7:480-6.